OKYO Pharma Announces Filing of Annual Report with Strengthened Cash Position and Accelerated Phase 3 Plans
LONDON and NEW YORK, July 20, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases …